News

Watch the Full Event Here.

Washington DC — Today, House Speaker Nancy Pelosi (D-CA), Majority Leader Steny H. Hoyer (D-MD), U.S. Representatives Peter Welch (D-VT-AL), Lauren Underwood (D-IL-14), and Susie Lee (D-NV-03), and Susan Wild (D-PA-07), and health care advocates and storytellers joined Protect Our Care for a press event to celebrate the Inflation Reduction Act’s game-changing measures to drive down health care costs for millions of working families and seniors nationwide. During the event, speakers discussed how the bill lowers premiums, gives Medicare the power to negotiate, caps drug costs for seniors, and reduces disparities in health care. 

Protect Our Care was also joined by David Mitchell, President and Founder of Patients for Affordable Drugs, Richard Fiesta, Executive Director at the Alliance for Retired Americans, and Emily Gee, vice president and coordinator for Health Policy at the Center for American Progress. 

“We’ve been trying for decades to enable the Secretary to negotiate for lower drug prices,” said U.S. Speaker of the House Nancy Pelosi (D-CA). “This is a kitchen table issue. It is something that is a value to us, and we finally were successful in this legislation. We want to do more, but we have kicked open that door.”

“If you have your health, you have everything,” said Majority Leader Steny H. Hoyer (D-MD). “We have taken action. Lower drug prices, better care — that’s what we did. Every American cares about health care.” 

“In addition to buying a Congress that held us hostage and kept us from doing what our job was for 16 years, Big Pharma preyed on the insecurity and the love that we have for people in our families who need medication. Those days are over with this price negotiation bill,” said U.S. Representative Peter Welch (D-VT-AL). “Let me say to Pharma: we have only begun to stop the rip off.” 

“We all share a story of someone in our family rationing or cutting their prescription drugs because they can’t afford it, or not paying their rent because they have to buy prescription drugs,” said U.S. Representative Susie Lee (D-NV-03). “We delivered on our promise to finally hold Big Pharma accountable — and not one Republican stood with us. We will continue to put people over politics.” 

“Today is one of my favorite days in Congress, because today is a health care day,” said U.S. Representative Lauren Underwood (D-IL-14). “The Inflation Reduction Act’s tax credits will make health care more accessible and affordable for 13 million Americans and help families of four save an average of $2,400 per year. Simply put, the Inflation Reduction Act is life changing.” 

“The Republicans have this mission that they are going to repeal the Inflation Reduction Act, and what that would mean to those 17,000 people in my district is that they would face a cliff where they can no longer afford their health insurance,” said U.S. Representative Susan Wild (D-PA-07). “We’re saving millions of dollars for taxpayers and we’re making health care more affordable and accessible. That’s real and it’s critically important. It’s an incredible victory to have passed the Inflation Reduction Act.” 

“For me, a single mom, and for so many West Virginians and Americans, passage of the Inflation Reduction Act is a game-changer. It’s a historic and significant legislative package that makes health coverage and prescription drugs more affordable for millions of Americans,” said Dr. Jessica Ice, patient storyteller from West Virginia. “In my home, it means saving more than $200 a month on health insurance premiums.” 

“As a two-time cancer survivor on Medicare, married to a type one diabetic on Medicare, the Inflation Reduction Act is a godsend,” said DonnaMarie Woodson, patient storyteller from North Carolina. “It improves the lives of millions of seniors across the country by lowering prescription drug costs and improving access to health care coverage. This piece of legislation is the greatest health care achievement since the passage of the Affordable Care Act — and the Affordable Care Act saved my life.” 

“The Inflation Reduction Act is a true victory for the American people,” said Protect Our Care Chair Leslie Dach. “We all know how high health care prices take a devastating toll on families when someone gets sick. After years of big drug companies and special interests pulling the strings in Washington, President Biden and Democrats delivered lower prescription drug and health care costs to millions of people — beginning as soon as next year. This legislation paves the way for a more affordable, accessible, and equitable health care system for many years to come.”

***MEDIA ADVISORY FOR WEDNESDAY SEPTEMBER 21 AT 10:00 AM ET***

Millions Will Benefit from Lower Health Care Costs and Better Care Thanks to the Inflation Reduction Act

Washington DC — On Wednesday, September 21, House Speaker Nancy Pelosi (D-CA) and Majority Leader Steny H. Hoyer (D-MD) will join U.S. Representatives Peter Welch (D-VT-AL), Lauren Underwood (D-IL-14), Susie Lee (D-NV-03), and Susan Wild (D-PA-07), and health care advocates and storytellers for an in-person press event hosted by Protect Our Care to celebrate the Inflation Reduction Act’s game-changing measures to drive down health care costs for millions of working families and seniors nationwide. During the event, speakers will discuss how the bill lowers premiums, gives Medicare the power to negotiate, caps drug costs for seniors, and reduces disparities in health care. These savings will begin as soon as next year. The event will take place in front of the House Triangle. 

WHO:
U.S. Speaker of the House Nancy Pelosi (D-CA)
Majority Leader Steny H. Hoyer (D-MD)
U.S. Representative Peter Welch (D-VT-AL)
U.S. Representative Susie Lee (D-NV-03)
U.S. Representative Lauren Underwood (D-IL-14)
U.S. Representative Susan Wild (D-PA-07)
David Mitchell, Patients for Affordable Drugs
Richard Fiesta, Alliance for Retired Americans
Emily Gee, Center for American Progress
Dr. Jessica Ice, patient storyteller from West Virginia
DonnaMarie Woodson, patient storyteller from North Carolina

WHAT: Press Event Celebrating Lower Health Care Costs

WHEN: Wednesday, September 21, 2022 at 10:00 AM ET

WHERE: House Triangle

Event will also be streamed live online here.

As the Inflation Reduction Act theme weeks come to a close, Protect Our Care is highlighting how the legislation will help patients with serious diseases like Parkinson’s Disease. The Inflation Reduction Act will drastically reduce the cost of prescription drugs for Americans enrolled in Medicare’s Part D drug benefit by allowing Medicare to negotiate drug prices, preventing drug companies from raising prices faster than the rate of inflation, and capping out-of-pocket spending on drugs to $2,000 a year for Medicare beneficiaries. This bill also extends enhanced American Care Act subsidies to allow more Americans to afford coverage, reducing racial, income, and geographic disparities in health care and saving lives. Nearly a million Americans with Parkinson’s will feel the direct financial impacts of affordable prescription drugs and health insurance from this bill.

By The Numbers:

• Premium tax credits extended in the Inflation Reduction Act will allow 13 million people with pre-existing conditions, including Parkinson’s, to save money on their insurance.
• Medications for Parkinson’s costs an average $14,177 per year, according to a 2021 study.
• An estimated 90 percent of people with Parkinson’s receive Medicare benefits costing $23 billion.
• Roughly 60,000 Americans suffer from Parkinson’s disease.

The Inflation Reduction Act Lowers Health Care Costs

Out-Of-Pocket Spending Caps On Prescription Drugs Benefits Parkinson’s Patients.  Medicare beneficiaries with serious conditions like multiple sclerosis, cancer, and rheumatoid arthritis could save thousands of dollars under the Inflation Reduction Act. In 2025, out-of-pocket costs for prescription drugs will be capped at $2,000 per year for medications covered by Medicare Part D; directly lowering costs for the more than 1.4 million enrollees who paid more than $2,000 on medication in 2020. A quarter of American adults have not filled a prescription, cutting pills in half, or skipped doses due to the cost of medication. Cost of Parkinson’s medications has caused patients to avoid taking their prescriptions or cut doses which can lead to worsening symptoms of the disease.

Extending Premium Subsidies Saves Lives. The Inflation Reduction Act extends enhanced premium subsidies through the end of 2025. Right now, nearly 13 million people, or 89 percent with an ACA plan, are receiving enhanced premium tax credits, making their coverage affordable and accessible. After two years of these subsidies, the Department of Health and Human Services released an analysis showing that just 8 percent of Americans lacked health insurance at the beginning of 2022 — an all-time low for the nation.

Gives Medicare The Power To Negotiate Lower Drug Prices. Under the Inflation Reduction Act, Medicare will be empowered to negotiate prices for select drugs for Medicare Part D’s 49 million beneficiaries. Beginning in 2026, 10 drugs will be negotiated with that number increasing to 15 drugs in 2027, and 20 drugs in 2029 and into the future. By 2030, more than 80 drugs will be eligible for Medicare price negotiation, in addition to insulin products. With 90 percent of people with Parkinson’s obtaining their health care through Medicare, drug price negotiation will largely benefit most Americans with this disease.

Minorities Suffer From Symptoms Of Parkinson’s More Than White People. Black Americans have greater Parkinson’s severity and disability than their white counterparts. This is most likely due to delayed diagnosis, lack of access to care, economic factors, and lack of referrals to specialists. There is little research on the prevalence of Parkinson’s in minority communities due to the socioeconomic factors of getting patients to receive proper care and to take part in research trials.

The final Inflation Reduction Act theme week focuses on how the historic legislation will help Americans with serious diseases, including multiple sclerosis (MS). Over the next few years, the Inflation Reduction Act will drastically reduce the cost of prescription drugs for Americans enrolled in Medicare’s Part D drug benefit by allowing Medicare to negotiate drug prices, preventing drug companies from raising prices faster than the rate of inflation, and capping out-of-pocket spending on drugs to $2,000 a year. This bill also extends enhanced American Care Act subsidies to allow more Americans to afford coverage, reducing racial, income, and geographic disparities in health care and saving lives. Organizations representing Americans with MS have pushed for the passage of the Inflation Reduction Act as it has direct financial impacts making prescription drugs and health insurance more affordable.

By The Numbers:

• Premium tax credits extended in the Inflation Reduction Act will allow 13 million people with pre-existing conditions, including MS, to save money on their insurance
• According to a 2017 study, medicines for MS cost an average $70,000 per year, roughly $4,000 out-of-pocket.
• 40 percent of people suffering from MS altered or stopped taking medication due to cost.
• There are nearly 1 million people in the United States living with MS.

The Inflation Reduction Act Lowers Health Care Costs

Capping Out-Of-Pocket Spending On Prescription Drugs Relieves Financial Stressors For Americans With MS.  Medicare beneficiaries with serious conditions like multiple sclerosis, cancer, and rheumatoid arthritis could save thousands of dollars under the Inflation Reduction Act. In 2025, out-of-pocket costs for prescription drugs will be capped at $2,000 per year for medications covered by Medicare Part D; directly lowering costs for the more than 1.4 million enrollees who paid more than $2,000 on medication in 2020. A quarter of American adults have not filled a prescription, cutting pills in half, or skipped doses due to the cost of medication. Americans with MS pay over $300 a month for their prescriptions. 

Extending Premium Subsidies Saves Lives. The Inflation Reduction Act extends enhanced premium subsidies through the end of 2025. Right now, nearly 13 million people, or 89 percent with an ACA plan, are receiving enhanced premium tax credits, making their coverage affordable and accessible. After two years of these subsidies, the Department of Health and Human Services released an analysis showing that just 8 percent of Americans lacked health insurance at the beginning of 2022 — an all-time low for the nation. Extending premium subsidies will allow more Americans who have MS to detect MS earlier and afford and access proper treatment.

Gives Medicare The Power To Negotiate Lower Drug Prices. Under the Inflation Reduction Act, Medicare will be empowered to negotiate prices for select drugs for Medicare Part D’s 49 million beneficiaries. Beginning in 2026, 10 drugs will be negotiated with that number increasing to 15 drugs in 2027, and 20 drugs in 2029 and into the future. By 2030, more than 80 drugs will be eligible for Medicare price negotiation, in addition to insulin products. MS patients will directly feel the effects of drug price negotiation with more than 25 percent of patients with MS being on Medicare. 

Inflation Reduction Act Will Help Minority Communities With Multiple Sclerosis. MS has been believed to be most prevalent among white women that are between ages 20 to 50. Recent research has shown that African Americans suffer more from the disease than previously thought. Studies from 2013 and 2020 show that Black women suffer from the highest rates of MS. MS also tends to have a more aggressive progression, greater disability symptoms, and more cognitive symptoms in Black MS patients than in white. Black, Hispanic, and other minority communities suffer from a lack of access to care. It is less likely that minorities see a neurologist or receive specialized care for MS than their white counterparts. The Inflation Reduction Act will help bridge the gap between minority communities and receiving the proper care they need to manage MS.

As part of the final Inflation Reduction Act theme week, Protect Our Care is highlighting how the historic legislation will help Americans with serious diseases, including diabetes. The Inflation Reduction Act will drastically reduce the cost of prescription drugs for Americans enrolled in Medicare’s Part D drug benefit by allowing Medicare to negotiate drug prices, preventing drug companies from raising prices faster than the rate of inflation, and capping out-of-pocket spending on drugs to $2,000 a year. This bill also extends enhanced American Care Act subsidies to allow more Americans to afford high-quality coverage, reducing racial, income, and geographic disparities in health care and saving lives. Millions of Americans with diabetes will feel the direct financial impacts of affordable prescription drugs and health insurance from this bill.

By The Numbers:

• 3.3 million Medicare beneficiaries with diabetes will benefit from a guarantee that their insulin costs are capped at $35 for a month’s supply.
• Premium tax credits extended in the Inflation Reduction Act will allow 13 million people with pre-existing conditions, including diabetes, to save money on their insurance
• Diabetes is the costliest chronic condition in America.
• More than 8 million people rely on prescription insulin.

The Inflation Reduction Act Lowers Health Care Costs

Capping Out-Of-Pocket Costs Will Help Millions Of Seniors With Diabetes Save Money.  Medicare beneficiaries with serious conditions like diabetes, multiple sclerosis, and rheumatoid arthritis could save thousands of dollars under the Inflation Reduction Act. In 2025, out-of-pocket costs for prescription drugs will be capped at $2,000 per year for medications covered by Medicare Part D; directly lowering costs for the more than 1.4 million enrollees who paid more than $2,000 on medication in 2020. A quarter of American adults have not filled a prescription, cutting pills in half, or skipped doses due to the cost of medication. One out of every four Americans with diabetes can’t afford their insulin. 

Extending Premium Subsidies Saves Lives. The Inflation Reduction Act extends enhanced premium subsidies through the end of 2025. Right now, nearly 13 million people, or 89 percent with an ACA plan, are receiving enhanced premium tax credits, making their coverage affordable and accessible. After two years of these subsidies, the Department of Health and Human Services released an analysis showing that just 8 percent of Americans lacked health insurance at the beginning of 2022 — an all-time low for the nation.

Gives Medicare The Power To Negotiate Lower Drug Prices. Under the Inflation Reduction Act, Medicare will be empowered to negotiate prices for select drugs for Medicare Part D’s 49 million beneficiaries. Beginning in 2026, 10 drugs will be negotiated with that number increasing to 15 drugs in 2027, and 20 drugs in 2029 and into the future. By 2030, more than 80 drugs will be eligible for Medicare price negotiation, in addition to insulin products. 

Every Republican In Congress Voted For Higher Insulin Prices For Americans With Diabetes. Every Republican in Congress voted against capping insulin copays for Medicare beneficiaries at $35 each month starting in 2023. Almost all Republicans in the Senate also voted to block applying the $35 monthly cap to people with private insurance, forcing higher prices onto millions of Americans with diabetes.

Affordable Insulin Directly Helps Minority And Rural Seniors. Minority Americans are disproportionately affected by diabetes when compared to their white counterparts with over 12 percent of Black adults and 11.8 percent of Hispanics being diagnosed with the disease. Black Americans also continue to be the hardest hit when it comes to affording their prescription drugs and paying medical bills. 

According to a 2018 study, rural Americans are 17 percent more likely to suffer from diabetes than urban Americans. Diabetes risk factors are higher in rural areas than their urban and suburban counterparts as they have less access to health care providers, fewer transportation options to receive care, and higher rates of being uninsured. 

These seniors are forced to stop taking their medication or cut doses in half. Diabetics suffer severe effects such as numbness in feet and nerve damage in the eyes when they stop taking doses as prescribed. Patients who suffer chronic complications can expect to pay upwards of an additional $650 per year. The insulin cap provision in the Inflation Reduction Act will vastly improve the lives of millions of older, minority, and rural insulin users.

Care Force One to Travel Across 21+ States, Make Over 40 Stops and Cover Nearly 12,000 Miles in Five Weeks Starting in October

Washington, D.C. — As President Biden is set to celebrate the passage of the Inflation Reduction Act at the White House today, Protect Our Care is announcing updates to its fourth nationwide bus tour, Lower Costs, Better Care: Help is on the Way. From Maine to Nevada, elected officials, storytellers, and health care advocates will celebrate The Inflation Reduction Act’s measures to drive down health care costs and to let Americans know how and when they can access these new benefits. Kicking off on October 3, Care Force One will roll into districts and states for events to educate Americans about how the bill could save them thousands of dollars a year on health care. Over five weeks, Care Force One will travel to more than 20 states, make more than 40 stops, and travel nearly 12,000 miles. 

“Care Force One will crisscross the nation this fall with one message: Thanks to President  Biden and Democrats in Congress, help is on the way,” said Protect Our Care Executive Director Brad Woodhouse. “President Biden and Democratic lawmakers took on unified Republican opposition and Big Pharma’s lobbying power to deliver lower premiums and prescription drug costs for millions of Americans. Throughout the tour, people from all walks of life will share what this bill means to them and their families. Between saving seniors thousands on their prescriptions and lowering monthly premium costs for working families, this bill stands to help millions afford lifesaving health care.” 

The “Lower Costs, Better Care” five-week tour will promote the work of lawmakers who fought tirelessly to pass this historic bill and hold Republicans accountable for rejecting measures to lower costs for the American people. Lawmakers have long promised to lower health costs and rein in high drug prices — but President Biden and Democrats actually got the job done. 

The Inflation Reduction Act will lower costs and improve health care for millions of Americans, with help on the way in just a matter of months. The legislation will lower premiums for 13 million Americans and drive down prescription drug prices by giving Medicare the power to negotiate, capping seniors’ out-of-pocket drug costs at $2,000 per year, limiting insulin copays, and stopping many of Big Pharma’s egregious price hikes. Decades in the making, this bill will help lower costs for millions of working families and seniors, and it will address the deep racial inequities in our health care system. Read more about The Inflation Reduction Act’s health care provisions here. 

Help Is On The Way – The Inflation Reduction Act By the Numbers

• 13 million Americans will save on their health insurance premiums starting in 2023, saving an average of $2,400 per family.
• 49 million Medicare beneficiaries will no longer face Big Pharma’s outrageous price hikes that outpace inflation beginning in 2023.
• $35 insulin copays for Medicare beneficiaries beginning in 2023.
• 49 million Medicare Part D beneficiaries will have out-of-pocket costs for prescription drugs capped at $2,000 per year beginning in 2025. 
• 80 of the most expensive prescription drugs will have lower prices because of Medicare negotiations by 2030.

Protect Our Care’s Care Force One will make stops in: 

Bangor, Maine on Monday, October 3, 2022
Laconia, New Hampshire on Monday, October 3, 2022
Concord, New Hampshire on Tuesday, October 4, 2022
Hartford, Connecticut on Tuesday, October 4, 2022
Allentown, Pennsylvania on Wednesday, October 5, 2022
Scranton, Pennsylvania on Wednesday, October 5, 2022
New Jersey on Thursday, October 6, 2022
Harrisburg/Pittsburgh, Pennsylvania on Friday, October 7, 2022
Morgantown, West Virginia on Friday, October 7, 2022
Cincinnati, Ohio on Monday, October 10, 2022
Cleveland, Ohio on Monday, October 10, 2022
Flint, Michigan on Tuesday, October 11, 2022
Lansing, Michigan on Tuesday, October 11, 2022
Milwaukee, Wisconsin on Wednesday, October 12, 2022
Green Bay, Wisconsin on Wednesday, October 12, 2022
Eau Claire, Wisconsin on Thursday, October 13, 2022
St. Paul, Minnesota on Thursday, October 13, 2022
Des Moines, Iowa on Friday, October 14, 2022
Kansas City, Missouri on Friday, October 14, 2022
Reno, Nevada on Monday, October 17, 2022
Las Vegas, Nevada on Tuesday, October 18, 2022
Flagstaff, Arizona on Tuesday, October 18, 2022
Phoenix, Arizona on Wednesday, October 19, 2022
Tucson, Arizona on Wednesday, October 19, 2022
Albuquerque, New Mexico on Thursday, October 20, 2022
Pueblo / Colorado Springs, Colorado on Thursday, October 20, 2022
Denver, Colorado on Friday, October 21, 2022
Richmond, Virginia on Monday, October 24, 2022
Raleigh, North Carolina on Monday, October 24, 2022
Charlotte, North Carolina on Tuesday, October 25, 2022
Augusta, Georgia on Tuesday, October 25, 2022
Atlanta, Georgia on Wednesday, October 26, 2022
Savannah, Georgia on Wednesday, October 26, 2022
Orlando, Florida on Thursday, October 27, 2022
Tampa, Florida on Thursday, October 27, 2022
Miami, Florida on Friday, October 28, 2022

TBA: October 31-November 4, 2022

Washington DC — Today, Protect Our Care enters the final Inflation Reduction Act theme week, which focuses on how the bill works to drive down health care costs for patients with cancer. Cancer is among the most expensive diseases to treat, forcing patients to pay thousands of dollars a year just to stay alive — and that’s if they are lucky enough to pay for care at all. Big drug companies have hiked the cost of cancer medications year after year, but that stops with the Inflation Reduction Act. The bill gives Medicare the power to negotiate drug prices and stops price hikes and caps out-of-pocket costs for seniors. Additionally, the historic legislation reduces premium costs for millions of Americans, ensuring people have access to affordable cancer screenings and treatment. 

“The Inflation Reduction Act is a godsend for the millions of Americans battling cancer and other serious diseases,” said Protect Our Care Executive Director Brad Woodhouse. “It is unconscionable that patients and their families are forced to worry about paying the bills while grappling with everything that comes with a cancer diagnosis. Now, thanks to President Biden and Democrats in Congress, and no thanks to a single Republican, relief is on the way to help folks pay for their prescription drugs, lower their premium costs, and give them peace of mind knowing they can access the care they need.” 

Throughout the week, Protect Our Care will continue to release fact sheets and host nationwide events with elected officials, storytellers, and health care advocates to highlight the Inflation Reduction Act’s critical measures to drive down health care and prescription drug costs.

Inflation Reduction Act Themed Weeks:

• Week 1: GOP Accountability. Week one focuses on how every Republican lawmaker in Congress stood by Big Pharma and other special interests and voted against lower health care costs for the American people.
• Week 2: Seniors. Week two is bringing attention to the Inflation Reduction Act’s provisions to lower prescription drug costs for millions of seniors. 
• Week 3: Lower Health Care Premiums. Week three focuses on how millions of Americans will save on their health care premiums thanks to the Inflation Reduction Act. 
• Week 4: Cancer. The final week highlights how patients fighting serious diseases like cancer stand to save thousands of dollars a year on their health care costs. 

FACT SHEET: The Inflation Reduction Act Lowers Costs For Americans With Cancer

The Inflation Reduction Act will drastically reduce the cost of prescription drugs for Americans enrolled in Medicare’s Part D drug benefit by allowing Medicare to negotiate drug prices, preventing drug companies from raising prices faster than the rate of inflation, and capping out-of-pocket spending on drugs to $2,000 a year for Medicare beneficiaries. This bill also extends enhanced Affordable Care Act subsidies to allow more Americans to afford coverage and help  reduce racial, income, and geographic disparities in health care and save lives. Millions of cancer patients and survivors will feel the direct financial impacts of affordable prescription drugs and health insurance from this bill.

By The Numbers:

• 30 percent of Medicare beneficiaries who face high prices for cancer treatments don’t fill their prescriptions.
• Medicare spent $5.4 billion on a cancer treatment drug Revlimid in 2020 alone.
• 1.4 million Medicare patients spend more than $2,000 on medications each year, including people who need high-cost cancer drugs
• Premium tax credits extended in the Inflation Reduction Act will allow 13 million people with pre-existing conditions, including cancer, to save money on their insurance

Read the full fact sheet here.

Kelley v. Becerra Threatens to End Free Lifesaving Preventive Health Care — From Contraception to Cancer Screenings — for 150 Million Americans

Watch the Full Event Here.

Washington DC — Today, U.S. Representative Bobby Scott (D-VA-03), legal experts and health care advocates joined Protect Our Care for a virtual press conference to discuss the latest developments in the Kelley v. Becerra lawsuit, which threatens lifesaving preventive care services guaranteed by the Affordable Care Act (ACA). 

This week, U.S. District Judge Reed O’Connor ruled to invalidate all of the benefits covered under the U.S. Preventive Services Task Force, including lifesaving colorectal and other cancer screenings, depression screenings, hypertension screenings, and access to PrEP (pre-exposure prophylaxis). Judge O’Connor’s ruling also threatens to wipe out free access to contraception, prenatal care, vaccinations, and more. More than 150 million Americans relied on these services in 2020. Read more about the case here.  

“For more than a decade, the Affordable Care Act has provided millions of Americans with access to preventive health care, such as cancer screenings, vaccinations, contraception, and chronic disease screenings, without having to pay anything out of pocket,” said House Education and Labor Committee Chairman Robert C. “Bobby” Scott (VA-03). “This week’s decision is a major step backwards and could prevent many Americans from accessing the preventive care they need to lead healthier lives. At a time when families are facing global inflation and women’s reproductive health care is under attack, we should be making health care more affordable and accessible. I remain committed to working with my colleagues, as well as organizations like Protect Our Care, to ensure Americans have access to the preventive care promised under the Affordable Care Act.”

“We know now that access to all of these incredibly important evidence-based preventive services are at risk,” said Katie Keith, Georgetown University. “If we lost these provisions, we would really return to a pre-Affordable Care Act era where each individual employer and insurance company can pick and choose what preventive services they want to cover and whether they can charge you cost sharing.” 

“Ultraconservative judges have bookended this summer with decisions that put our bodies and lives on the line,” said Sharita Gruberg, VP for Economic Justice at the National Partnership for Women & Families. “Judge O’Connor’s opinion craters the full spectrum of preventative care by invalidating the coverage requirements set forth by the United States Preventive Services Task Force, which is made up of experts at the top of their field who Judge Reed O’Connor is not one of.”

“There is a misconception that this decision only impacts a limited number of health services. In reality, this lawsuit threatens health care for more than 150 million Americans, including people with employer coverage,” said Protect Our Care Chair Leslie Dach. “Guaranteed access to free preventive care is a life or death issue, protecting people from serious diseases, reducing stark disparities in care, and ensuring children and families stay healthy. Let’s be clear: this case is politically-driven, brought by longtime adversaries of the ACA, women’s health, and LGBTQ rights. This lawsuit comes at a time when Republicans in Congress have vowed to repeal the ACA, entirely sunset Social Security and Medicare, and repeal the Inflation Reduction Act’s provisions to lower drug prices. The consequences of this ruling cannot be understated and it is essential that Judge O’Connor stay the effects of his order while this dangerous decision is appealed.”